Highlights of ASH in CLL
John Gribben et al.
The characteristics and mode of action of ibrutinib for CLL
Overview of Bruton's tyrosine kinase (BTK) inhibitors in chronic lymphocytic leukemia
ASH 2015 highlights by Prof. Michael Hallek
CLL update from ICML17: Current treatment and future directions for patients